Ironwood Pharmaceuticals (IRWD) Competitors

$3.52 -0.16 (-4.22%)

As of 01:14 PM Eastern

IRWD vs. ABBV, CLDX, BCRX, INVA, and NVAX

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? MarketBeat compares Ironwood Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ironwood Pharmaceuticals include AbbVie (ABBV), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "medical" sector.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to AbbVie's net margin of 5.79%. Ironwood Pharmaceuticals' return on equity of -39.65% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
AbbVie	5.79%	-576.45%	13.39%

70.2% of AbbVie shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AbbVie had 57 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 62 mentions for AbbVie and 5 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.18 beat Ironwood Pharmaceuticals' score of 0.31 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbbVie	39 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	1.95	$24.02M	$0.60	5.91
AbbVie	$61.16B	6.06	$4.23B	$2.03	103.26

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 75.83%. AbbVie has a consensus target price of $253.43, suggesting a potential upside of 20.90%. Given Ironwood Pharmaceuticals' higher probable upside, equities analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Ironwood Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Celldex Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,615.93	-$258.76M	-$4.26	N/A
Ironwood Pharmaceuticals	$296.15M	1.95	$24.02M	$0.60	5.91

In the previous week, Celldex Therapeutics had 7 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 12 mentions for Celldex Therapeutics and 5 mentions for Ironwood Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.88 beat Ironwood Pharmaceuticals' score of 0.31 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Celldex Therapeutics' net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Celldex Therapeutics presently has a consensus target price of $49.78, indicating a potential upside of 57.00%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 75.83%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Ironwood Pharmaceuticals beats Celldex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Ironwood Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, indicating a potential upside of 75.83%. BioCryst Pharmaceuticals has a consensus price target of $20.70, indicating a potential upside of 124.63%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

BioCryst Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	1.95	$24.02M	$0.60	5.91
BioCryst Pharmaceuticals	$874.84M	2.68	$263.86M	-$1.78	N/A

In the previous week, BioCryst Pharmaceuticals had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 13 mentions for BioCryst Pharmaceuticals and 5 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.31 beat BioCryst Pharmaceuticals' score of 0.27 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has a net margin of 28.26% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ironwood Pharmaceuticals' return on equity of -39.65% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Innoviva?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, indicating a potential upside of 75.83%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 63.40%. Given Ironwood Pharmaceuticals' higher possible upside, research analysts clearly believe Ironwood Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Ironwood Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

99.1% of Innoviva shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Ironwood Pharmaceuticals and Ironwood Pharmaceuticals both had 5 articles in the media. Innoviva's average media sentiment score of 0.82 beat Ironwood Pharmaceuticals' score of 0.31 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Ironwood Pharmaceuticals' net margin of 28.26%. Innoviva's return on equity of 33.33% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Innoviva	119.89%	33.33%	22.67%

Innoviva has higher revenue and earnings than Ironwood Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	1.95	$24.02M	$0.60	5.91
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69

Summary

Innoviva beats Ironwood Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Novavax currently has a consensus price target of $12.13, suggesting a potential upside of 32.47%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 75.83%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Novavax has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

53.0% of Novavax shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Novavax had 14 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 19 mentions for Novavax and 5 mentions for Ironwood Pharmaceuticals. Novavax's average media sentiment score of 0.76 beat Ironwood Pharmaceuticals' score of 0.31 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Novavax has higher revenue and earnings than Ironwood Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.34	$440.30M	-$0.58	N/A
Ironwood Pharmaceuticals	$296.15M	1.95	$24.02M	$0.60	5.91

Summary

Ironwood Pharmaceuticals beats Novavax on 9 of the 17 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$578.05M	$2.99B	$6.24B	$12.27B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	5.91	18.10	20.39	25.30
Price / Sales	1.95	261.46	539.22	73.02
Price / Cash	14.30	57.78	43.26	56.33
Price / Book	-2.67	4.32	9.83	6.90
Net Income	$24.02M	$72.19M	$3.55B	$333.62M
7 Day Performance	-16.00%	-2.20%	0.73%	-0.15%
1 Month Performance	-18.88%	-2.58%	-0.59%	1.68%
1 Year Performance	496.40%	41.31%	36.42%	32.68%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	3.2404 of 5 stars	$3.52 -4.2%	$6.23 +77.3%	+465.5%	$573.16M	$296.15M	5.86	220	Gap Down
ABBV AbbVie	4.9249 of 5 stars	$202.81 +0.6%	$252.90 +24.7%	+19.0%	$356.37B	$61.16B	99.91	57,000	Trending News Analyst Forecast Analyst Revision
CLDX Celldex Therapeutics	3.1887 of 5 stars	$32.28 -5.0%	$48.00 +48.7%	+71.3%	$2.67B	$1.54M	N/A	150	Analyst Forecast Analyst Revision
BCRX BioCryst Pharmaceuticals	3.7493 of 5 stars	$8.58 -0.5%	$20.70 +141.3%	-2.8%	$2.19B	$874.84M	N/A	530
INVA Innoviva	4.1108 of 5 stars	$22.52 -1.6%	$36.20 +60.7%	+26.9%	$1.70B	$411.33M	3.75	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, CLDX, BCRX, INVA, and NVAX

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, CLDX, BCRX, INVA, and NVAX

How does Ironwood Pharmaceuticals compare to AbbVie?

Is IRWD or ABBV more profitable?

Do institutionals & insiders hold more shares of IRWD or ABBV?

Does the media refer more to IRWD or ABBV?

Which has preferable valuation & earnings, IRWD or ABBV?

Do analysts recommend IRWD or ABBV?

Which has more volatility and risk, IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to Celldex Therapeutics?

Which has more volatility and risk, CLDX or IRWD?

Which has preferable valuation and earnings, CLDX or IRWD?

Does the media prefer CLDX or IRWD?

Is CLDX or IRWD more profitable?

Do analysts rate CLDX or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Which has more volatility & risk, IRWD or BCRX?

Do analysts recommend IRWD or BCRX?

Which has preferable valuation & earnings, IRWD or BCRX?

Does the media favor IRWD or BCRX?

Is IRWD or BCRX more profitable?

Do insiders & institutionals believe in IRWD or BCRX?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Do analysts recommend IRWD or INVA?

Which has more volatility & risk, IRWD or INVA?

Do insiders & institutionals believe in IRWD or INVA?

Does the media favor IRWD or INVA?

Is IRWD or INVA more profitable?

Which has preferable valuation & earnings, IRWD or INVA?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Do analysts prefer NVAX or IRWD?

Which has more volatility & risk, NVAX or IRWD?

Do institutionals & insiders have more ownership in NVAX or IRWD?

Does the media refer more to NVAX or IRWD?

Is NVAX or IRWD more profitable?

Which has higher valuation & earnings, NVAX or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools